Extended Data Fig. 5: Characterization of anti-RBDDelta antibody subclasses and Fc receptor binding following IM or IN vaccination with MC3 or Lipid 331 LNPs encapsulating either mRBDDelta or mRBDDelta-C3d. | Nature Biomedical Engineering

Extended Data Fig. 5: Characterization of anti-RBDDelta antibody subclasses and Fc receptor binding following IM or IN vaccination with MC3 or Lipid 331 LNPs encapsulating either mRBDDelta or mRBDDelta-C3d.

From: Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA

Extended Data Fig. 5

a, MFIs of antibody features obtained from Luminex assay measuring serological antibody binding against the RBD antigen from the Delta variant of SARS-CoV-2. Serum was collected from mice vaccinated with either mRBDDelta in MC3 or Lipid 331 LNPs (MC3 and 331, respectively), mRBDDelta-C3d in MC3 or Lipid 331 LNPs (MC3 + C3d and 331 + C3d, respectively), or PBS. Data related to vaccination study in Fig. 4. b, Ratio of IgG2c to IgG1 levels as a surrogate of Th1-Th2 bias. Ratios were calculated as log10(MFIIgG2c)/log10(MFIIgG1). n = 5, statistical significance was analysed using a one-way ANOVA with post-hoc Tukey test. Data are presented as mean ± SD.

Back to article page